<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ESTROGENS, ESTERIFIED</span><br/>(ess'tro-jenz)<br/><span class="topboxtradename">Estratab, </span><span class="topboxtradename">Menest, </span><span class="topboxtradename">Menrium, </span><span class="topboxtradename">Neo-Estrone <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">hormones and synthetic substitutes</span>; <span class="classification">estrogen</span><br/><b>Prototype: </b>Estradiol<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.3 mg, 0.625 mg, 1.25 mg, 2.5 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Combination of same estrogens as found in conjugated estrogens, but in different proportions.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Binds to intracellular receptors that stimulate DNA and RNA to synthesize proteins responsible for effects of estrogen.</p>
<h1><a name="uses">Uses</a></h1>
<p>Atrophic vaginitis, kraurosis vulvae and abnormal bleeding (hormonal imbalance), female hypogonadism, castration, primary
         ovarian failure, vasomotor symptoms associated with menopause, palliative therapy of breast and prostatic carcinomas; prevention
         of osteoporosis.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Breast cancer; known or suspected pregnancy (category X); lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypertension; gallbladder disease; diabetes mellitus; heart failure; liver or kidney dysfunction; history of thromboembolic
         disease.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Menopause</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.31.25 mg/d for 21 d each month, adjust to lowest level that gives symptom control (<img src="../images/special/lesserorequal.gif"/>0.625
               mg/d)<br/><br/><span class="indicationtitle">Female Hypogonadism, Primary Ovarian Failure, Female Castration</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2.57.5 mg/d in 13 divided doses for 20 d followed by a 10-d rest period, during last 5 d of estrogen, give a PO
               progestin<br/><br/><span class="indicationtitle">Breast Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 10 mg t.i.d. for 23 mo<br/><br/><span class="indicationtitle">Prostatic Cancer (palliation)</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1.252.5 mg t.i.d. for several weeks<br/><br/><span class="indicationtitle">Prevention of Osteoporosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.3 mg q.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food or fluid of patient's choice.</li>
<li>Give cyclically, except when used for palliation of cancer.</li>
<li>Store tablets at 15°30° C (59°86° F) in a tightly closed container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, dizziness, depression, <span class="speceff-common">libido changes.</span> <span class="typehead">CV:</span> <span class="speceff-life">Thromboembolic disorders</span>, hypertension. <span class="typehead">GI:</span> <span class="speceff-common">Nausea</span>, vomiting, diarrhea, bloating, cholestatic jaundice. <span class="typehead">Urogenital:</span> Mastodynia, spotting, changes in menstrual flow, dysmenorrhea, amenorrhea. <span class="typehead">Metabolic:</span> Reduced carbohydrate tolerance, fluid retention. <span class="typehead">Other:</span> Leg cramps, intolerance to contact lenses. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">barbiturates</span>, <b>phenytoin,</b> <b>rifampin</b> decrease estrogen effect by increasing its metabolism; <span class="classification">oral anticoagulants</span> may decrease hypoprothrombinemic effects; interfere with effects of <b>bromocriptine;</b> may increase levels and toxicity of <b>cyclosporine,</b> <span class="classification">tca</span>s, <b>theophylline;</b> decrease effectiveness of <b>clofibrate.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed with first pass metabolism. <span class="typehead">Metabolism:</span> Metabolized in GI mucosa and liver to estrone, further metabolized to inactive metabolites. <span class="typehead">Elimination:</span> Excreted in urine and bile. <span class="typehead">Half-Life:</span> 418.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>See nursing implications under estradiol.</li>
<li>Monitor for and report break-through vaginal bleeding.</li>
<li>Assess for relief of menopausal symptoms.</li>
<li>Lab tests: Monitor serum phosphatase levels with prostate cancer.</li>
<li>Monitor bone density annually when used for osteoporosis prophylaxis.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware of importance of taking drug exactly as prescribed: Specifically, do not omit, increase, or decrease doses without
            advice of physician. Know what to do when a dose is missed.
         </li>
<li>Review package insert to ensure understanding of estrogen therapy.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>